June 30 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd.

LOS ANGELES--()--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the June 30, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC) securities between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”). ImmunoCellular investors have until June 30, 2017 to file a lead plaintiff motion in this putative class action lawsuit. To obtain information or participate in the class action, please visit the ImmunoCellular page on our website at www.glancylaw.com/case/immunocellular-therapeutics-ltd.

According to the complaint filed in this class action, starting in 2011, ImmunoCellular hired Lidingo Holdings, LLC to “pump up” the value of ImmunoCellular's stock. Allegedly, Lidingo paid people to write fake media reports that undeservedly touted ImmunoCellular stock. While the articles appeared to be unbiased and genuine on the surface, in actuality the articles were paid promotions wherein ImmunoCellular had complete editorial control of the authors' work. As a result of this deception, investors were made to believe that ImmunoCellular's studies for ICT-107 were progressing positively, leading the company's stock price to reach a high of $3.88 per share on June 1, 2012. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against the Company, as well as other individuals and entities for engaging in unlawful stock promotion activities.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired ImmunoCellular shares during the Class Period you may move the Court no later than June 30, 2017 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Release Summary

June 30 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd.

$Cashtags

Social Media Profiles

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com